| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;103:1289.)
© 2001 American Heart Association, Inc.
Basic Science Reports |
From the First Department of Internal Medicine and Institute for Experimental Animals (M.S.), Kobe (Japan) University School of Medicine.
Correspondence to Mitsuhiro Yokoyama, MD, First Department of Internal Medicine, Kobe University School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. E-mail yokoyama{at}med.kobe-u.ac.jp
| Abstract |
|---|
|
|
|---|
Methods and ResultsContractile responses to serotonergic agents of endothelium-denuded coronary arteries from control and Watanabe heritable hyperlipidemic rabbits (WHHL) were examined. WHHL coronary arteries exhibited hypercontraction to 5-HT1receptor agonists; the constrictor threshold concentrations and ED50 to serotonin, 5-carboxamidotryptamine, and sumatriptan in WHHL were significantly lower, and the Emax in WHHL to these agents were increased 55% to 59% above those of the control. Serotonin-evoked contractions in both groups were inhibited by GR127935 (5-HT1B/1D antagonist; 0.1 to 1 nmol/L) and pertussis toxin but not by ketanserin (5-HT2 antagonist; 0.01 to 1 µmol/L), suggesting that the hypercontraction is most likely mediated by 5-HT1B/1D receptors through a pertussis toxinsensitive pathway. Furthermore, simultaneous measurements of [Ca2+]i and isometric tension of fura-2loaded arteries revealed that the hypercontraction was concomitant with the augmented elevation of [Ca2+]i in the smooth muscle. The 5-HT1B mRNA levels in WHHL coronary arteries increased to 2.5-fold over those in control arteries, whereas neither 5-HT1D nor 5-HT2A mRNA was detected in either group.
ConclusionsAtherosclerotic rabbit coronary arteries exhibited the enhancement in contraction and Ca2+ mobilization in response to serotonin. The 5-HT1B receptor, which is upregulated by atherosclerosis, most likely mediates the augmenting effects of serotonin.
Key Words: atherosclerosis vasoconstriction receptors muscle, smooth
| Introduction |
|---|
|
|
|---|
Coronary spasm is well known to occur at the site of atherosclerotic lesions.10 Isolated coronary arteries from patients with variant angina are associated with atherosclerosis and exhibit enhanced susceptibility to the constrictor effect of serotonergic agents.11 12 In addition, an increase in the response to serotonergic agents has been documented in vessels isolated from animal models of vasospasm or atherosclerosis.13 14 15 These lines of evidence suggest that the augmented vasocontraction to serotonin, in relation to atherosclerosis, may principally contribute to the genesis of myocardial ischemia. However, the precise mechanism of the serotonin-evoked hypercontraction in atherosclerotic vessels is unclear. The aim of this study was to clarify the mechanism responsible for the altered vasoreactivity to serotonin in atherosclerotic coronary arteries by using Watanabe heritable hyperlipidemic rabbits (WHHL), the established animal model of atherosclerosis.16
| Methods |
|---|
|
|
|---|
Isometric Tension Measurement of Coronary
Arterial Strips
Isometric tension of coronary strips was measured as
previously
described.13 17
Briefly, coronary strips were suspended in organ baths containing Krebs
buffer, and an initial preload of 0.5 g was applied. After 2 hours
for equilibration, test contractions were induced by adding 20 mmol/L
KCl. When the developed tension attained its peak value, strips were
relaxed by rinsing with buffer. The concentration-response relations
were determined by cumulative additions of serotonin,
5-carboxamidotryptamine (5-CT; 5-HT1 receptor
agonist), sumatriptan (SUM; 5-HT1B/1D receptor
agonist), phenylephrine (PE;
1-adrenoceptor
agonist), and histamine (HIS). Constrictor threshold concentrations,
one-half maximally effective dose (ED50) values,
and maximum responses (Emax) were determined
from the log concentration-response curve for each agonist. In the
antagonist studies, vessel strips were treated with indicated
concentrations of GR127935 (5-HT1B/1D receptor
antagonist) or ketanserin (5-HT2 receptor
antagonist) for 30 minutes before addition of agonists.
To verify the technique for functional denudation of endothelium, vasodilator responses were examined. Vessel rings with or without endothelium were precontracted by addition of 1 µmol/L PE. After the contraction reached a plateau, substance P was added in a cumulative manner.
In a subset of assays with pertussis toxin (PTX), after initial concentration-response curves to serotonin and HIS were obtained, coronary strips were incubated at 37°C for 12 hours in Krebs buffer containing 200 ng/mL PTX or vehicle. The PTX-containing buffer was changed every 3 hours and kept oxygenated. Coronary strips showed comparable contractions to 20 mmol/L KCl before and after treatment with PTX. Concentration-response curves to serotonin and HIS obtained after PTX treatment were compared with those obtained after vehicle treatment.
Simultaneous Measurement of Muscle Tension and
[Ca2+]i in Coronary
Strips
Isometric tension and cytosolic
Ca2+ concentration
([Ca2+]i) in
coronary strips were measured with a CAF110 fluorometer (JASCO), as
described previously.18
Coronary strips were treated with 6 µmol/L of the acetoxymethyl ester
of fura-2 in the presence of 0.02% cremophor EL for 3 to 4 hours at
room temperature. The muscle strip was illuminated alternately by a
xenon lamp with 2 excitation wavelengths (340 and 380 nm). The
intensity of fluorescence induced by excitation at 340 nm
(F340) and 380 nm (F380)
was measured, the ratio
(F340/F380) was
calculated automatically, and absolute
[Ca2+]i was
obtained according to the previously reported
method.18 After the tissue
was conditioned by application of high K+
(72.7 mmol/L), the concentration-response relations for serotonin and
SUM were determined. We measured muscle tension and
F340/F380 when the level
had reached the sustained phase for each dose of the agent. Muscle
tension and [Ca2+]i
values in the resting state were taken as 0%, and those in the high
K+-stimulated state were taken as
100%.
Ribonuclease Protection Assay
With the use of rabbit brain cDNA as a template, the
cDNA regions of rabbit 5-HT1B,
5-HT1D receptor, and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were amplified by polymerase chain reactions for
35 cycles at 93°C, 56°C, and 72°C for 1, 2, and 3 minutes,
respectively, with the following primers (GenBank accession number in
parenthesis).
5-HT1B (Z50163); 5'-GCGGAATTCTCCCAGATCGCAGTTCCTCAAGCCAACCTC-3' 5'-GTGGTCGACAGGCGATCAGGTAATTAGCCGGGGTGTGCA-3' 5-HT1D (Z50162); 5'-ATGTCCCCATCAAACCAGTCGGCAGA-3' 5'-AGGACAAAGGTGTTGGAGAGGACCGT-3' GAPDH (J00657); 5'-GCGGAATTCCCATTCATTGACCTCCAC-TACATGG-3' 5'-TCTGTCGACGATCTCGCTCCTGGAAGATGGTGA-3'.
The amplified cDNA fragments were cloned with TA cloning vectors and sequenced by the dideoxy method. Rabbit 5-HT2A receptor was cloned from a rabbit brain cDNA library (T. Ishida et al, unpublished data, 2000) and the 5' region of this gene was ligated in the pGEM-4Z vector. Ribonuclease protection assay was as performed with the radiolabeled antisense riboprobes.19 The relative signal intensity of 5-HT1B receptor mRNA expression was standardized with that of GAPDH mRNA.
Statistics
Results are expressed as mean±SEM. An unpaired
Students t test was used to
detect significant differences when 2 groups were compared. Statistical
differences among group means were determined by ANOVA with Bonferroni
correction. A value of P<0.05
was taken as significant.
Drugs
The following drugs were used: 5-hydroxytryptamine
creatinine sulfate,
L-phenylephrine
hydrochloride, and histamine diphosphate (Sigma);
5-carboxamidotryptamine maleate, sumatriptan, and GR127935
hydrochloride monohydrate (gifts from Glaxo Wellcome); ketanserin
tartrate (a gift from Janssen Pharmaceutica); and pertussis toxin
(Research Biochemicals
International).
| Results |
|---|
|
|
|---|
|
|
We next examined the effects of GR127935 and ketanserin. As
depicted in
Figure 2A
, low concentrations of GR127935 (0.1 to 1 nmol/L)
inhibited the serotonin-evoked contraction in a dose-dependent manner.
The high antagonist potency of GR127935 in both coronary preparations
strongly implies that 5-HT1B and/or
5-HT1D receptors mediate the contractile
responses. As is the case with previous
studies,20 a significant
reduction of Emax
(P<0.05) by GR127935 was
observed. On the other hand, low concentrations of ketanserin (0.01 to
0.1 µmol/L) did not affect the serotonin-evoked
(Figure 2B
), 5-CTevoked, or SUM-evoked (data not shown)
contractions. Although higher concentrations of ketanserin (1 µmol/L)
slightly inhibited the serotonin effects, the inhibition was not
statistically significant. Notably, GR127935 inhibited 5-CTevoked and
SUM-evoked contractions
(Figure 2C
), whereas ketanserin did not (data not shown) in
control coronary artery strips. These results strongly support that
GR127935-sensitive (ie, 5-HT1B/1D) receptors
mainly contribute to the contraction by
serotonin.
|
PTX Attenuated Serotonin- Evoked
Vasoconstriction
To investigate the signaling pathway in the
serotonin-evoked contraction, coronary strips were treated with 200
ng/mL PTX for 12 hours. As shown in
Figure 3A
, the significant reduction of contractile
responses to serotonin was observed in the PTX-treated vessels in both
control (74.0±7.8% reduction,
P<0.01) and WHHL (72.1±5.1%
reduction, P<0.01). On the
other hand, the histamine-evoked contraction, which is mediated through
Gq protein, was not attenuated by treatment with PTX in either group
(Figure 3B
). Together, this indicates that serotonin-evoked
contractions in both WHHL and control are mediated through
PTX-sensitive mechanisms.
|
Serotonin-Evoked Hypercontraction Was
Associated With Augmented Ca2+
Mobilization
The muscle tension and
[Ca2+]i in
fura-2loaded coronary strips were simultaneously measured in response
to serotonin and SUM. In the resting state,
[Ca2+]i levels in
control arteries and WHHL coronary arteries were 212±17 and 225±29
nmol/L, respectively. In the high
K+stimulated (72.7 mmol/L) state,
[Ca2+]i levels in
control arteries and WHHL coronary arteries were 2206±342 and
2345±351 nmol/L, respectively. There were no significant differences
in tension and
[Ca2+]i between
control and WHHL in both resting and high
K+stimulated states. Therefore, we used
the percentage values of tension and
[Ca2+]i of those
induced by high K+ and compared relative
changes in [Ca2+]i
in WHHL with those in control.
By contrast, in response to serotonin, WHHL coronary
arteries exhibited enhanced Emax of
[Ca2+]i and tension
as compared with the control arteries
(Figure 4
, A and B). The serotonin-induced elevation of
[Ca2+]i in smooth
muscles of WHHL was augmented in association with the enhanced
contractile response. Furthermore, SUM mimicked the augmenting effects
of serotonin in WHHL. Similar to serotonin, SUM-induced enhanced
contraction in WHHL was concomitant with the augmented elevation of
[Ca2+]i in smooth
muscles
(Figure 4
, C and D). These findings indicate that stimulation
of 5-HT1B/1D receptors causes
Ca2+ mobilization in smooth muscles and that
the hypercontraction to serotonin in atherosclerotic rabbit coronary
arteries is associated with augmented receptor-mediated
Ca2+ mobilization in smooth
muscles.
|
5-HT1B Receptor mRNA
Levels Are Increased in Atherosclerotic Coronary Arteries
To evaluate gene expression of 5-HT receptors, we
performed a ribonuclease protection assay. Cohybridization of rabbit
5-HT1B receptor and GAPDH riboprobes with rabbit
coronary artery RNA, followed by digestion with single strandspecific
ribonucleases and denaturing polyacrylamide gel electrophoresis,
yielded the protected riboprobe fragments of 225 and 142 bases in
length, consistent with the 5-HT1B receptor and
GAPDH, respectively
(Figure 5A
, lanes 4 to 7). Expression levels of
5-HT1B receptor mRNA were increased by
2.5±0.2-fold (P<0.05) in WHHL
compared with those in control
(Figure 5A
, lanes 4, 5 versus lanes 6, 7). In contrast, there
were no significant differences in 5-HT1B
receptor mRNA expression in whole brain between the groups
(Figure 5A
, lane 8 versus lane 9). On the other hand, neither
5-HT2A
(Figure 5C
) nor 5-HT1D mRNA (data not
shown) was detected by this assay. Therefore, serotonin, 5-CT, and SUM
were considered to selectively stimulate 5-HT1B
receptors in rabbit coronary arteries. Together, the data indicate that
the 5-HT1B receptor is functionally expressed
and is the major subtype in the rabbit coronary
artery.
|
| Discussion |
|---|
|
|
|---|
In general, two plausible explanations may account for the increase in potency of serotonin: impaired endothelium-dependent relaxation and hypercontraction of the smooth muscle. In this study, the hypercontraction in atherosclerotic arteries is considered to result from the altered reactivity of vascular smooth muscle cells per se because we verified histologically that endothelium has been removed from the vessel strips and that endothelium-dependent relaxation to substance P was abolished in our coronary preparations. It is likely that atherosclerosis changes the function of 5-HT receptors in vascular smooth muscle. We speculate that this abnormality in serotonin-evoked Ca2+ mobilization in the smooth muscle is a key step in the development of enhanced susceptibility to serotonin in atherosclerotic rabbit coronary arteries.
It has been postulated that rabbit coronary artery is an example of a tissue in which contractions to serotonin are mediated mainly by 5-HT1like receptors.17 21 In our study, SUM as well as 5-CT mimicked the serotonin effects, and serotonin-evoked contraction was inhibited by low concentrations of GR127935 in both groups, supporting the involvement of 5-HT1B and/or 5-HT1D receptors. 5-HT1B and 5-HT1D receptors have been reported to have remarkable pharmacological similarities and are difficult to distinguish from one another despite their low sequence homology. Notably, it has been reported that 1 µmol/L ketanserin blocks the 5-HT1D but not the 5-HT1B subtype on recombinant receptors.22 Thus, in combination with previous reports,17 21 we speculate that the predominant 5-HT receptor in rabbit coronary arteries is most likely the 5-HT1B subtype. Furthermore, detection of 5-HT1B mRNA but not 5-HT1D or 5-HT2A mRNA in the coronary strips is consistent with the involvement of 5-HT1B receptors. From the standpoint of pharmacological analysis, however, we could not completely rule out the involvement of 5-HT1D receptors regarding the effect of atherosclerosis. In this study, we did not use specific antagonists for these receptors, and to make a sharp distinction between 5-HT1B and 5-HT1D receptors, the effects of specific antagonists for these receptors should be examined in the future.
Although activation of 5-HT1 receptors is believed to be coupled with an inhibitory G protein, the precise intracellular signal transduction system of this receptor is still obscure. Particularly, there is little evidence that activation of this receptor causes Ca2+ mobilization in vascular tissues leading to contraction. Previous studies have demonstrated that activation of both 5-HT1B and 5-HT1D receptors causes [Ca2+]i elevation through the PTX-sensitive mechanism in other cells.23 24 In this study, we have verified that activation of endogenous vascular 5-HT1B/1D receptors by SUM and serotonin causes Ca2+ mobilization and subsequent contraction through a PTX-sensitive pathway in vascular tissue preparations. Moreover, this is the first study demonstrating that activation of endogenous vascular 5-HT1B receptors contribute to hypercontractions, concomitant with augmented Ca2+ mobilization in atherosclerotic vessels.
Expression levels of 5-HT1B receptor mRNA in WHHL coronary arteries were increased to 2.5-fold of those in control. In contrast, neither 5-HT1D nor 5-HT2A mRNA was detected. Upregulation of the 5-HT1B receptor mRNA may not directly reflect the receptor protein or its function. We could not quantify the receptor protein levels because of low expression levels. However, we speculate that the enhanced responsiveness to serotonin is related to the upregulation of the 5-HT1B receptor mRNA. That is, an increase in 5-HT1B receptor number would account for the increase in the vascular responsiveness to serotonin, particularly in the reduction in threshold serotonin concentrations required for the response. Interestingly, we found an increase in the 5-HT1B receptor mRNA in the human coronary arteries with atheroma.25 Further studies are required to clarify the mechanism of the upregulation of this gene and its contribution to hypercontraction.
It has been reported that serotonin-evoked contractions of human large coronary arteries are mediated by both 5-HT1B and 5-HT2A receptors.19 22 26 Kaumann et al22 have demonstrated that the relative contribution of these receptors in vasoconstriction of human coronary arteries was not directly related to the degree of atherosclerosis. On the other hand, some studies have indicated that ketanserin-resistant (or 5-HT1) receptors predominantly participate in constrictions of coronary arteries in patients with atherosclerosis or coronary artery diseases.8 27 28 Moreover, isolated coronary arteries from patients with variant angina exhibited enhanced susceptibility to SUM as well as serotonin and ergonovine.11 12 Recent intravascular ultrasound studies have shown that atherosclerosis is present at sites with coronary vasospasm even in the absence of angiographically significant coronary artery disease.29 Although our present findings are based on rabbit coronary arteries and vascular response to serotonin largely varies among species, vascular beds, age, and disease status, we speculate that 5-HT1B receptors could possibly account for the ketanserin-resistant pathogenic constriction in patients with atherosclerosis or coronary spasm.
Conclusions
Atherosclerotic rabbit coronary arteries exhibited
enhanced contraction in response to serotonin. Augmented
Ca2+ mobilization in smooth muscle may be
the principal mechanism of the hypercontraction. The responses are
mainly mediated by activation of GR127935-sensitive receptors. In
particular, the 5-HT1B receptor, which is
upregulated by atheroma, most likely mediates the serotonin effects.
Our findings might provide a novel role of this receptor in the
abnormal modulation of vascular tone in atherosclerotic
arteries.
| Acknowledgments |
|---|
Received July 12, 2000; revision received September 28, 2000; accepted October 1, 2000.
| References |
|---|
|
|
|---|
2.
Willerson JT,
Golino P, Eidt J, et al. Specific platelet mediators and unstable
coronary artery lesions: experimental evidence and potential clinical
implications. Circulation. 1989;80:198205.
3.
Van den Berg EK,
Schmitz JM, Benedict CR, et al. Transcardiac serotonin concentration is
increased in selected patients with limiting angina and complex
coronary lesion morphology.
Circulation. 1989;79:116124.
4. Rubanyi GM, Frye RL, Holmes DR Jr, et al. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol. 1987;9:12431249.[Abstract]
5. Egashira K, Tomoike H, Hayashi Y, et al. Mechanism of ergonovine-induced hypercontraction of the large epicardial coronary artery in conscious dogs a month after arterial injury. Circulation. 1992;71:435442.
6. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med. 1991;324:641648.[Abstract]
7. McFadden EP, Clarke JG, Davies GJ, et al. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med. 1991;324:648654.[Abstract]
8.
McFadden EP,
Bauters C, Lablanche JM, et al. Effect of ketanserin on proximal and
distal coronary constrictor responses to intracoronary infusion of
serotonin in patients with stable angina, patients with variant angina,
and control patients.
Circulation. 1992;86:187195.
9. Kanazawa K, Suematsu M, Ishida T, et al. Disparity between serotonin- and acetylcholine-provoked coronary artery spasm. Clin Cardiol. 1997;20:146152.[Medline] [Order article via Infotrieve]
10. MacAlpin RN. Relation of coronary arterial spasm to sites of organic stenosis. Am J Cardiol. 1983;46:143153.
11.
Ishida T, Hirata
K, Sakoda T, et al. 5-HT1Dß receptor mediates
the supersensitivity of isolated coronary artery to serotonin in
variant angina. Chest. 1998;113:243244.
12. Yokoyama M, Akita H, Hirata K, et al. Supersensitivity of isolated coronary artery to ergonovine in a patient with variant angina. Am J Med. 1990;89:507515.[Medline] [Order article via Infotrieve]
13.
Yokoyama M, Akita
H, Mizutani T, et al. Hyperreactivity of coronary arterial smooth
muscles in response to ergonovine from rabbits with hereditary
hyperlipidemia. Circ Res. 1983;53:6371.
14. Henry PD, Yokoyama M. Supersensitivity of atherosclerotic rabbit aorta to ergonovine: mediation by a serotonergic mechanism. J Clin Invest. 1980;66:306313.
15.
Heisted DD,
Armstrong ML, Marcus ML, et al. Augmented responses to vasoconstrictor
stimuli in hypercholesterolemic and atherosclerotic monkeys.
Circ Res. 1984;54:711718.
16.
Shiomi M, Ito T,
Tsukada T, et al. Cell compositions of coronary and aortic
atherosclerotic lesions in WHHL rabbits differ: an immunohistochemical
study. Arterioscler Thromb. 1994;14:931937.
17. Awano K, Yokoyama M, Fukuzaki H. Role of serotonin, histamine, and thromboxane A2 in platelet-induced contractions of coronary arteries and aortae from rabbits. J Cardiovasc Pharmacol. 1989;13:781792.[Medline] [Order article via Infotrieve]
18.
Miwa Y, Hirata K,
Matsuda Y, et al. Augmented receptor-mediated
Ca2+ mobilization causes supersensitivity of
contractile response to serotonin in atherosclerotic arteries.
Circ Res. 1994;75:10961102.
19.
Ishida T, Sakoda
T, Hirata K, et al. Identification of mRNA for
5-HT1 and 5-HT2 receptor
subtypes in human coronary arteries.
Cardiovasc Res. 1999;41:267274.
20. Terrón JA. GR127935 is a potent antagonist of the 5-HT1-like receptor mediating contraction in the canine coronary artery. Eur J Pharmacol. 1996;300:109112.[Medline] [Order article via Infotrieve]
21.
Félétou M,
Dellazuana O, Duhault J. Serotoninergic receptor subtype in coronary
artery smooth muscle from young and atherosclerotic rabbit.
J Pharmacol Exp Ther. 1994;268:124132.
22.
Kaumann AJ,
Frenken M, Posival H, et al. Variable participation of
5-HT1-like receptors and
5-HT2 receptors in serotonin-induced contraction
of human isolated coronary arteries: 5-HT1like
receptors resemble cloned 5-HT1Dß receptors.
Circulation. 1994;90:11411153.
23. Dickenson JM, Hill SJ. Coupling of an endogenous 5-HT1B-like receptor increases in intracellular calcium through a pertussis toxin-sensitive mechanism in CHO-K1 cells. Br J Pharmacol. 1995;116:28892896.[Medline] [Order article via Infotrieve]
24.
Zgombick JM,
Borden LA, Cochran TL, et al. Dual coupling of cloned human
5-hydroxytryptamine1D
and
5-hydroxytryptamine1Dß receptors stably
expressed in murine fibroblasts: inhibition of adenylate cyclase and
elevation of intracellular calcium concentrations via pertussis
toxin-sensitive G protein(s). Mol
Pharmacol. 1993;44:575582.[Abstract]
25. Ishida T, Sakoda T, Hirata K, et al. Molecular analysis of serotonin (5-hydroxytryptamine) receptors in human coronary arteries. Jpn Circ J. 1997;61:621. Abstract.
26.
Kaumann AJ,
Parsons AA, Brown AM. Human arterial constrictor serotonin receptors.
Cardiovasc Res. 1993;27:20942103.
27.
Chester AH,
Martin GR, Bodelsson M, et al. 5-Hydroxytryptamine receptor profile in
healthy and diseased human epicardial coronary arteries.
Cardiovasc Res. 1990;24:932937.
28.
Caterina RD,
Carpeggiani C, Abbate AL. A double-blind, placebo-controlled study of
ketanserin in patients with Prinzmetals angina: evidence against a
role for serotonin in the genesis of coronary vasospasm.
Circulation. 1984;69:889894.
29. Koyama J, Yamagishi M, Tamai J, et al. Comparison of vessel wall morphologic appearance at sites of focal and diffuse coronary vasospasm by intravascular ultrasound. Am Heart J. 1995;130:440445.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
E. Marcos, E. Fadel, O. Sanchez, M. Humbert, P. Dartevelle, G. Simonneau, M. Hamon, S. Adnot, and S. Eddahibi Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension Circ. Res., May 14, 2004; 94(9): 1263 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bhattacharya, K. W. Schenck, Y.-C. Xu, L. Nisenbaum, E. Galbreath, and M. L. Cohen 5-Hydroxytryptamine1B Receptor-Mediated Contraction of Rabbit Saphenous Vein and Basilar Artery: Role of Vascular Endothelium J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 825 - 832. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |